Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has
ushered in a new era of anti-tumor therapy, with sustained responses and significant survival …

Over the last decade, based on the extensive development of preclinical animal studies and
clinical trials, the efficacy, and mechanisms of immunotherapy have been fully explored. …

Lung cancer is the most common malignant tumor with the highest mortality, and about 84%
are non-small cell lung cancer (NSCLC). However, only a small proportion of patients with …

Cancer cells adapt to increasing energy and biosynthetic demands by reprogramming their
metabolic pathways. Mitochondria are important organelles for the metabolic reprogramming …

Tumor immune microenvironment is a very complex system that is influenced by a wide range
of factors; in this microenvironment, various immune cells, stromal cells, and cytokines can …

Metabolic reprogramming is one of the important characteristics of cancer and is a key process
leading to malignant proliferation, tumor development and treatment resistance. A variety …

The most common driver gene mutation in patients with non‐small‐cell lung cancer (NSCLC)
is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR‐…

Antibodies targeting programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1)
have been considered breakthrough therapies for a variety of solid and hematological …

Objective. We aimed to retrospectively analyze the predictors of immune checkpoint inhibitors
(ICIs)-efficacy in patients with advanced pancancer who were treated with various ICIs in …

Background The long noncoding RNA HOX transcript antisense RNA (HOTAIR) is highly
expressed in breast cancer (BC) tissues and is associated with the recurrence and metastasis …